About NeoVista
NeoVista is a company based in Newark (United States) founded in 2002. It operates as a B2B. NeoVista has raised $114.42 million across 12 funding rounds from investors including The Carlyle Group, GE Capital and Oxford Finance. NeoVista operates in a competitive market with competitors including Kodiak Sciences, Pixium Vision, Second Sight, Eyedaptic and iScience Interventional, among others.
- Headquarter Newark, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$114.42 M (USD)
in 12 rounds
-
Latest Funding Round
$5.19 M (USD), Series D
May 11, 2012
-
Investors
The Carlyle Group
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of NeoVista
NeoVista has successfully raised a total of $114.42M across 12 strategic funding rounds. The most recent funding activity was a Series D round of $5.19 million completed in May 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NeoVista
NeoVista has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include The Carlyle Group, GE Capital and Oxford Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt firm focused on the life sciences sector
|
Locked | Locked | Locked | |
|
Early-stage US healthcare investments are made by Accuitive Medical Ventures.
|
Locked | Locked | Locked | |
|
Private equity investments are directed toward multiple sectors.
|
Locked | Locked | Locked |
Investor details for NeoVista
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NeoVista
Investment portfolio details for NeoVista
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NeoVista
Detailed financials for NeoVista
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neovista Comparisons
Peer comparison for NeoVista
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NeoVista
NeoVista operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kodiak Sciences, Pixium Vision, Second Sight, Eyedaptic and iScience Interventional, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for retinal diseases are developed by the company.
|
|
| Locked | Locked | Locked |
Bionic vision restoration systems are provided for sight restoration.
|
|
| Locked | Locked | Locked |
Implantable visual prosthetics for blind individuals are developed and provided.
|
|
| Locked | Locked | Locked |
A wearable augmented reality vision assistance solution
|
|
| Locked | Locked | Locked |
Microcatheter and imaging technologies for ophthalmic procedures are developed.
|
|
| Locked | Locked | Locked |
Develops ophthalmic products for ophthalmic system manufacturers
|
Detailed competitors of NeoVista
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neovista
Complete news archive for NeoVista
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NeoVista
NeoVista was founded in 2002 and raised its 1st funding round 1 year after it was founded.
NeoVista is headquartered in Newark, United States. It is registered at Newark, New Jersey, United States.
NeoVista is a funded company, having raised a total of $114.42M across 12 funding rounds to date.
NeoVista operates with a B2B model, focusing on providing healthcare solutions, developing medical devices, ophthalmology, and degeneration treatment. Delivers tailored solutions for treating age-related macular degeneration. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
NeoVista's top competitors include Kodiak Sciences, Second Sight and Pykus Therapeutics.
NeoVista has 8 investors. Key investors include The Carlyle Group, GE Capital, Oxford Finance, Accuitive Medical Ventures, and Turmeric Acquisition Corp.